Corticosteroids in Duchenne muscular dystrophy: Major variations in practice

Muscle and Nerve

Volumn 48, Issue 1, 2013, Pages 27-31

  Griggs, Robert C ^a   Herr, Barbara E ^a   Reha, Allen ^b   Elfring, Gary ^b   Atkinson, Leone ^b   Cwik, Valerie ^c   Mccoll, Elaine ^d   Tawil, Rabi ^a   Pandya, Shree ^a   Mcdermott, Michael P ^a   Bushby, Kate ^d  

^a UNIVERSITY OF ROCHESTER   (United States)

^b PTC THERAPEUTICS   (United States)

^c Muscular Dystrophy Association   (United States)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Corticosteroids; Deflazacort; Duchenne muscular dystrophy; Equipoise; Prednisone; Treatment of muscular dystrophy

Indexed keywords

DEFLAZACORT; PLACEBO; PREDNISONE;

ARTICLE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG USE; DUCHENNE MUSCULAR DYSTROPHY; HEALTH CARE SURVEY; HUMAN; PATIENT CARE; PRIORITY JOURNAL;

ADRENAL CORTEX HORMONES; CLINICAL TRIALS, PHASE II AS TOPIC; DATA COLLECTION; EUROPE; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; PHYSICIANS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES;

EID: 84879551364     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23831     Document Type: Article

References (37)

1. Mendell JR, Shilling C, Leslie ND, Flanigan KM, al-Dahhak R, Gastier-Foster J, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 2012;71:304-313.
2. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Florence J, et al. Duchenne dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology 1989;39:475-481.
3. Simonds AK, Muntoni F, Heather S, Fielding S. Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy. Thorax 1998;53:949-952.
4. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 2002;12:926-929.
5. Ishikawa Y, Miura T, Aoyagi T, Ogata H, Hamada S, Minami R. Duchenne muscular dystrophy: survival by cardiorespiratory interventions. Neuromuscul Disord 2011;21:47-51.
6. Bushby K, Finkle R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010;9:177-189.
7. Bushby KMD, Muntoni F, Bourke JP. 107th ENMC International workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002 Naarden, The Netherlands. Neuromuscul Disord 2003;13:166-172.
8. Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, Bécane HM. Effect of perindropril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005;45:855-857.
9. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurology 2010;9:77-93.
10. Drachman DB, Toyka KV, Myer E. Prednisone in Duchenne muscular dystrophy. Lancet 1974;2:1409-1412.
11. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2004(2);CD003725.
12. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008;CD003725.
13. Bushby K, Muntoni F, Urtizberea A, Hughes R, Griggs R. Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the uses of corticosteroids. 2-4 April 2004, Naarden, The Netherlands. Neuromuscular Disord 2004;14:526-534.
14. Moxley RT, Ashwal S, Pandya S, Connolly A, Florence J, Mathews K, et al. Corticosteroid treatment of Duchenne dystrophy [Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society]. Neurology 2005;64:13-20.
15. Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, et al. Randomized double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989;320:1592-1597.
16. Griggs RC, Moxley RT, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, et al. Prednisone in Duchenne dystrophy: a randomized, controlled trial defining the time course and dose response. Arch Neurol 1991;48:383-388.
17. Fenichel GM, Mendell JR, Moxley RT, Griggs RC, Brooke MH, Miller JP, et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol 1991;48:575-579.
18. Griggs RC, Moxley RT, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, et al. Duchenne dystrophy: Randomized controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 1993;43:520-527.
19. Fenichel GM, Florence JM, Pestronk A, Mendell JR, Moxley RT 3rd, Griggs RC, et al. Long term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991;41:1874-1877.
20. Biggar WD, Gingras, M, Fehlings DL, Harris VA, Steele CA. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr 2001;138:45-50.
21. Silversides CK, Webb GD, Harris VA, Biggar WD. Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol 2003;91:769-772.
22. Biggar WD, Politano L, Harris VA, Passamano L, Vajsar J, Alman B, et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscul Disord 2004;14:476-482.
23. Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006;16:249-255.
24. Sansome A, Royston P, Dubowitz V. Steroids in Duchenne muscular dystrophy; pilot study of a new low-dosage schedule. Neuromuscul Disord 1993;3:567-569.
25. Backman E, Henriksson KG. Low dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscul Disord 1995;5:233-241.
26. Carter GT McDonald CM. Preserving function in Duchenne dystrophy.with long-term pulse prednisone therapy. Am J Phys Med Rehabil 2000;79:455-458.
27. Connolly A, Schierbecker J, Renna R, Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne dystrophy. Neuromuscul Disord 2002;12:917-925.
28. Dubowitz V, Kinali MEA. Remission of clinical signs in early Duchenne dystrophy on intermittent low-dosage prednisolone therapy. Eur J Paediatr Neurol 2002;6:153-159.
29. Kinali M, Mercuri E, Main M, Muntoni F, Dubowitz V. An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy. Neuromuscul Disord 2002;12(suppl 1):S169-174.
30. Merlini L, Cicognani A, Malaspina E, Gennari M, Gnudi S, Talim B, et al. Early prednisone treatment in Duchenne muscular dystrophy. Muscle Nerve 2003;27:222-227.
31. Wong B. Presented at the American Academy of Neurology annual meeting, Toronto, April 2010.
32. Matthews DJ, James KA, Miller LA, Pandya S, Campbell KA, Ciafaloni E, et al. Use of corticosteroids in a population-based cohort of boys with Duchenne and Becker muscular dystrophy. J Child Neurol 2010;25:1319-1324.
33. Moxley RT, Pandya S, Ciafaloni E, Fox DJ, Campbell K. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 2010;25:1116-1129.
34. Escolar DM, Hache LP, Clemens PR, Cnaan A, McDonald CM, Viswanathan V, et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 2011;77:444-452.
35. Bushby K, Griggs R. 145th ENMC International Workshop: Planning for an international trial of steroid dosage regimes in DMD (FOR DMD) 22-24th October 2006, Naarden, The Netherlands. Neuromuscul Disord 2007;17:423-428.
36. Ricotti V, Ridout DA, Scott E, Quinlivan R, Robb SA, Manzur AY, et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 2012 Dec 18 (Epub ahead of print).
37. Scully MA, Cwik V, Marshall BC, Ciafaloni E, Getchius T, Griggs RC. Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data? Neurology 2013;80:583-589.